##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q/A

Amendment No. 1 to Form 10-Q

(Mark One)x
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 for the quarterly period ended June 30, 2003oro
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 for the transition period from

to


Commission File Number: 000-19122

APHTON CORPORATION

---

(Exact name of registrant as specified in its charter)


Delaware
    
    95-3640931(State or other jurisdiction of
incorporation or organization)
    
    (I.R.S. Employer Identification No.)80 SW Eighth Street, Miami, Florida
    
    33130(address of principal executive offices)
    
    (Zip Code)


(305) 374-7338

---

(Registrants telephone number, including area code)




---

(Former name, former address and former fiscal year, if changed since last report)


Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

x   Yes     o   No

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act).

x   Yes     o   No

Indicate the number of shares outstanding of each of the issuers classes of
common stock, as of the latest practicable date:

Class
    
    Number of
Shares outstanding
    
    As ofCommon Stock, $0.001 par value
    
    29,514,463
    
    February 24, 2004






---

TABLE OF CONTENTS



|                               |                                                                                               |                                      |  |  |  |  |  | 
|------------------------------ | --------------------------------------------------------------------------------------------- | ------------------------------------ |  |  |  |  |  | 
|Part I  Financial Information
|                               | Item 1. Financial Statements                                                                 
|                               |                                                                                               | Balance Sheets                      
|                               |                                                                                               | Statements of Operations (Unaudited)
|                               |                                                                                               | Statements of Cash Flows (Unaudited)
|                               | Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
|Signatures                    
|Section 302- Certification CEO
|Section 302- Certification CFO
|Section 906- Certification CEO
|Section 906- Certification CFO



---



##### Table of Contents



APHTON CORPORATION

Index

Amendment No. 1 to Form 10-Q amends and restates certain items of the Quarterly
Report of Aphton Corporation (the Company) on Form 10-Q as previously filed
for the three and six months ended June 30, 2003. The restatement of certain
items of the Companys previously filed Form 10-Q for the three and six months
ended June 30, 2003 and 2002 is being made in order to (i) correct an
application of certain accounting rules relating to our $20 million convertible
notes financing in the 2nd quarter of 2003; and (ii) revise related
disclosures. Changes related to these items have been made in the following
items of the Form 10-Q:

PagePart I  Financial Information
    
    
    3Item 1. Financial Statements:
    
    
    3Balance Sheets  June 30, 2003 (unaudited) and December 31, 2002
    
    
    4Statements of Operations (unaudited)  Three and six months ended June 30, 2003 and 2002
    
    
    5Statements of Cash Flows (unaudited)  Six months ended June 30, 2003 and 2002
    
    
    6Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    8Signatures
    
    
    13


2



---



##### Table of Contents






Part I  Financial Information






|        |  |                     
|------- |  | --------------------
|Item 1. |  | Financial Statements

The interim financial statements included herein have been prepared by us,
without audit, pursuant to the rules and regulations of the Securities and
Exchange Commission. In the opinion of management, the financial statements
include all adjustments (consisting of normal recurring entries) necessary to
present fairly our financial position as of June 30, 2003 and December 31, 2002
and the results of our operations for the three and six months ended June 30,
2003 and 2002; and our cash flows for the six months ended June 30, 2003 and
2002. It is suggested that these financial statements be read in conjunction
with the financial statements and the notes thereto included in our latest
annual report on Form 10-K.

3



---



##### Table of Contents



APHTON CORPORATION
Balance Sheets




Assets
    
    June 30, 2003
    
    December 31, 2002(unaudited)
RestatedCurrent Assets:Cash and current investments:Cash and short-term cash investments
    
    $
    10,068,687
    
    
    $
    7,824,182Investment securities-trading
    
    
    880,516
    
    
    
    749,095Total cash and current investments
    
    
    10,949,203
    
    
    
    8,573,277Other assets (including current portion of
unconditional supply commitment)
    
    
    301,326
    
    
    
    374,740Total current assets
    
    
    11,250,529
    
    
    
    8,948,017Equipment and improvements, at cost,
net of accumulated depreciation and amortization
    
    
    197,386
    
    
    
    245,063Unconditional supply commitment
    
    
    6,797,900
    
    
    
    6,797,900Total assets
    
    $
    18,245,815
    
    
    $
    15,990,980Liabilities and Stockholders DeficitLiabilities:Current liabilities:Trade accounts payable
    
    $
    3,703,773
    
    
    $
    10,130,944Amounts payable to Aventis
    
    
    3,184,000
    
    
    
    3,184,000Other
    
    
    1,135,516
    
    
    
    1,001,673Total current liabilities
    
    
    8,023,289
    
    
    
    14,316,616Convertible debentures, net of discount of
$12,723,508 as of June 30, 2003
    
    
    10,276,492
    
    
    
    3,000,000Deferred revenue
    
    
    10,000,000
    
    
    
    10,000,000Total liabilities
    
    
    28,299,781
    
    
    
    27,316,616CommitmentsStockholders Deficit:Preferred stock, $0.001 par value -
Authorized: 4,000,000 shares -
Issued and outstanding: none
    
    
    
    
    
    
    Common stock, $0.001 par value -
Authorized: 60,000,000 shares
Issued and outstanding: 24,701,639 shares at
June 30, 2003 and 24,201,639 shares
at December 31, 2002
    
    
    24,702
    
    
    
    24,202Additional paid in capital
    
    
    142,950,159
    
    
    
    128,956,652Purchase warrants
    
    
    317,650
    
    
    
    298,900Accumulated deficit
    
    
    (153,346,477
    )
    
    
    (140,605,390
    )Total stockholders deficit
    
    
    (10,053,966
    )
    
    
    (11,325,636
    )Total liabilities and stockholders deficit
    
    $
    18,245,815
    
    
    $
    15,990,980


4



---



##### Table of Contents






APHTON CORPORATION
Statements of Operations (Unaudited)
For the three and six months ended June 30, 2003 and 2002

Three months ended June 30,
    
    Six months ended June 30,2003
    
    2002
    
    2003
    
    2002Restated
    
    
    
    RestatedRevenue:
    
    $
    
    
    
    $
    
    
    
    $
    
    
    
    $
    Costs and expenses:General and administrative
    
    
    698,507
    
    
    
    564,495
    
    
    
    1,278,969
    
    
    
    953,927Research and development
    
    
    6,652,299
    
    
    
    9,311,658
    
    
    
    11,004,533
    
    
    
    19,001,905Total costs and expenses
    
    
    7,350,806
    
    
    
    9,876,153
    
    
    
    12,283,502
    
    
    
    19,955,832Loss from operations
    
    
    (7,350,806
    )
    
    
    (9,876,153
    )
    
    
    (12,283,502
    )
    
    
    (19,955,832
    )Other income (expense):Dividend and interest income
    
    
    16,775
    
    
    
    49,325
    
    
    
    30,485
    
    
    
    71,613Amortized discount and interest expense
    
    
    (520,000
    )
    
    
    
    
    
    
    (520,000
    )
    
    
    Unrealized
gains (losses) from investments
    
    
    35,891
    
    
    
    (7,870
    )
    
    
    31,930
    
    
    
    (37,515
    )Net lossPer share data:
    
    $
    (7,818,140
    )
    
    $
    (9,834,698
    )
    
    $
    (12,741,087
    )
    
    $
    (19,921,734
    )Basic and fully diluted loss per common share
    
    $
    (0.32
    )
    
    $
    (0.49
    )
    
    $
    (0.52
    )
    
    $
    (1.03
    )Weighted average number of common
shares outstanding
    
    
    24,701,639
    
    
    
    20,101,639
    
    
    
    24,618,306
    
    
    
    19,420,924


5



---



##### Table of Contents






APHTON CORPORATION
Statements of Cash Flows (Unaudited)
For the six months ended June 30, 2003 and 2002

Cash flows from operating activities:
    
    2003
    
    2002Cash paid to suppliers and employees
    
    $
    (18,759,784
    )
    
    $
    (21,176,416
    )Net cash used in operating activities
    
    
    (18,759,784
    )
    
    
    (21,176,416
    )Cash flows from investing activities:Purchase of held to maturity securities
    
    
    
    
    
    
    (1,311,203
    )Proceeds from maturity of held to maturity securities
    
    
    
    
    
    
    2,323,229Capital expenditures
    
    
    
    
    
    
    (16,490
    )Net cash provided by investing activities
    
    
    
    
    
    
    995,536Cash flows from financing activities:Sales of securities
    
    
    1,069,289
    
    
    
    27,652,154Proceeds from convertible debentures
    
    
    19,935,000
    
    
    
    Net cash received from financing activities
    
    
    21,004,289
    
    
    
    27,652,154Net increase in cash and short-term cash investments
    
    
    2,244,505
    
    
    
    7,471,274Cash and short-term cash investments:Beginning of period
    
    
    7,824,182
    
    
    
    3,176,717End of period
    
    $
    10,068,687
    
    
    $
    10,647,991Reconciliation of net loss to net cash used in operating activitiesNet loss
    
    $
    (12,741,087
    )
    
    $
    (19,921,734
    )Adjustments to reconcile net loss to net cash used in operating
activities:Depreciation and amortization
    
    
    47,677
    
    
    
    36,241Amortization of discount on convertible debentures
    
    
    220,000
    
    
    
    Unrealized gains from investments
    
    
    31,930
    
    
    
    37,515Non-cash employee compensation credit
    
    
    (31,930
    )
    
    
    (37,515
    )Changes in -Investment securities- trading
    
    
    (131,421
    )
    
    
    (1,892
    )Other assets
    
    
    138,394
    
    
    
    133,867Unconditional supply commitment
    
    
    
    
    
    
    250,000Current liabilities
    
    
    (6,293,347
    )
    
    
    (1,672,898
    )Net cash used in operating activities:
    
    $
    (18,759,784
    )
    
    $
    (21,176,416
    )


6



---



##### Table of Contents



Updated Notes to the Financial Statements

Restatement

The Company has restated its Consolidated Financial Statements for the three-
and six-month periods ended June 30, 2003 to reflect a recalculation of the
value of the beneficial conversion feature (BCF) attributable to the Companys
issuance of $20.0 million convertible debentures. The Company previously
recorded a discount to the convertible notes, and a corresponding
entry to additional paid in capital, in accordance with the Emerging Issues Task Force (EITF)
No. 98-5, Accounting for Convertible Securities with Beneficial Conversion
Features or Contingently Adjustable Conversion Ratios. The beneficial
conversion feature represents the non-detachable conversion feature that is
in-the-money at the commitment date and is valued by allocating a portion of
the proceeds from the issuance of the convertible debentures equal to the
intrinsic value of that feature to additional paid-in-capital. Pursuant to the
original calculation, the Company had previously recorded an unamortized
discount of $18.1 million as of June 30, 2003 with respect to the two tranches
of the convertible debentures the Company. However, it has recently come to
the Companys attention that the amount of the discount assigned to the BCF
should have been limited to the amount of the proceeds allocated to the
convertible instrument. As a result, the Company is restating the discount
associated with the convertible debentures as of June 30, 2003
to reduce it by $5.3 million,
which is an offset to the recorded amount of the convertible debentures. There
is also a corresponding decrease in Additional Paid in Capital of $5.6
million, a decrease in Accumulated Deficit of $0.3 million and an increase
in Total Stockholders Deficit of $5.3 million.
Further, this restatement resulted in a change to the Companys interest expense and net
loss for the three- and six-month period ended June 30, 2003 to reduce the
amounts previously reported by $0.3 million.

Comprehensive Loss
The net loss for the three and six months ended June 30, 2003 and 2002 was the
comprehensive loss for those periods. At June 30, 2003, shares of our common
stock issuable upon the exercise of approximately 5.1 million warrants and
options were excluded from the computation of net loss per share because their
effect was anti-dilutive. At June 30, 2002, shares of our common stock
issuable upon the exercise of approximately 3.7 million warrants and options
were excluded from the computation of net loss per share because their effect
was anti-dilutive.

Stock-Based Compensation
On December 31, 2002, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards (SFAS) No. 148, Accounting for Stock-Based
Compensation  Transition and Disclosure. This Statement amends SFAS No. 123,
Accounting for Stock-Based Compensation, to provide alternative methods of
transition for an entity that voluntarily changes to the fair value based
method of accounting for stock-based employee compensation. It also amends the
disclosure provisions of that Statement to require prominent disclosure about
the effects on reported net income of an entitys accounting policy decisions
with respect to stock-based employee compensation. Finally, this Statement
amends APB Opinion No. 28, Interim Financial Reporting, to require disclosure
about those effects in interim financial information. We intend to continue to
account for stock-based compensation based on the provisions of APB Opinion No.
25.

The following table summarizes our results as if we had recorded stock-based
compensation expense for the six months ended June 30, 2003 and June 30, 2002,
based on the provisions of SFAS 123, as amended by SFAS 148:

Net loss:
    
    June 30, 2003
    
    June 30, 2002RestatedAs reported
    
    $
    (12,741,087
    )
    
    $
    (19,921,734
    )Compensation expense, net of tax
    
    
    (286,252
    )
    
    
    (141,564
    )Pro forma
    
    $
    (13,027,339
    )
    
    $
    (20,063,298
    )Basic loss per share:As reported
    
    $
    (0.52
    )
    
    $
    (1.03
    )Compensation expense, net of tax
    
    
    (0.01
    )
    
    
    Pro forma
    
    $
    (0.53
    )
    
    $
    (1.03
    )Diluted loss per share:As reported
    
    $
    (0.53
    )
    
    $
    (1.03
    )Compensation expense, net of tax
    
    
    (0.01
    )
    
    
    Pro forma
    
    $
    (0.54
    )
    
    $
    (1.03
    )


7



---



##### Table of Contents



Convertible Debentures
As of June 30, 2003 we had outstanding $23.0 million in
face value of convertible
debentures, up from $3.0 million as of December 31, 2002. There was an initial
discount calculated against the value of the notes of $12.9 million, comprised
of the beneficial conversion feature of $8.3 million and other discounts of
$4.6 million on the notes. The unamortized discount as of June 30, 2003 of
$12.7 million is offset against the $23.0 million and is shown as $10.3 million
of convertible debentures in the accompanying financial statements. Of this
amount, $3.0 million is our Series A Convertible Debenture. Our Series A
Convertible Debenture is a convertible, redeemable, five-year note that matures
on December 19, 2007. The Series A Convertible Debenture bears interest at a
rate of 11.0% per annum, payable annually. The debenture is convertible at the
holders option at a conversion price equal to the average closing price of our
common stock, as defined in the debenture, at the time of conversion. The
Series A Convertible Debenture contains provisions that place a cap on the
number of shares of our common stock issuable upon its conversion, such that
the holder thereof shall not have the right to convert any portion of the
Series A Convertible Debenture to the extent that after giving effect to such
conversion the holders would beneficially own more than 19.99% of the number of
shares of our common stock outstanding immediately prior to such conversion.

The remaining $20.0 million in convertible notes were issued in two tranches to
accredited investors during the six months ended June 30, 2003. On April 4,
2003, we issued $15.0 million of convertible, redeemable, 5-year,
interest-bearing senior convertible notes (which we refer to as our 2003 senior
convertible notes) and 5-year warrants to purchase an aggregate total of
1,080,000 shares of our common stock to various accredited investors. On June
12, 2003 we issued an additional $5 million of our 2003 senior convertible
notes and a 5-year warrant to purchase an aggregate total of 360,000 shares of
our common stock to an accredited investor. The senior convertible notes
mature on March 31, 2008. The senior convertible notes bear interest at a rate
of 6.0% per annum, payable quarterly in cash or shares of our common stock, at
our option.

The senior convertible notes are convertible at a fixed price of $2.50 per
share, unless otherwise adjusted prior to conversion pursuant to the price
adjustment provisions set forth therein. The conversion price of the senior
convertible notes will be lowered in the event of a sale by us of our common
stock or securities convertible into our common stock at a per share offering
price less than the conversion price of the senior convertible notes in effect
immediately prior to such sale. The warrants are exercisable into shares of
our common stock at $2.70 per share, unless otherwise adjusted prior to
exercise pursuant to the price adjustment provisions that are substantially
similar to those set forth in the senior convertible notes. The senior
convertible notes and the warrants contain provisions that place a cap on the
numbers of shares of our common stock issuable upon their conversion or
exercise, such that the holders thereof shall not have the right to convert any
portion of the notes to the extent that after giving effect to such conversion
the holders would beneficially own more than 19.99% or 4.99%, as the case may
be for the respective holder, of the number of shares of our common stock
outstanding immediately prior to such conversion or exercise.




Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations

The Company has restated its Consolidated Financial Statements for the three-
and six-month periods ended June 30, 2003 to reflect a recalculation of the
value of the beneficial conversion feature (BCF) attributable to the Companys
issuance of $20.0 million convertible debentures. The Company previously
recorded a discount to the convertible notes, and a corresponding entry to
additional paid in capital, in accordance with the Emerging Issues Task Force (EITF)
No. 98-5, Accounting for Convertible Securities with Beneficial Conversion
Features or Contingently Adjustable Conversion Ratios. The beneficial
conversion feature represents the non-detachable conversion feature that is
in-the-money at the commitment date and is valued by allocating a portion of
the proceeds from the issuance of the convertible debentures equal to the
intrinsic value of that feature to additional paid-in-capital. Pursuant to the
original calculation, the Company had

8



---



##### Table of Contents



previously recorded an unamortized
discount of $18.1 million as of June 30, 2003 with respect to the two tranches
of the convertible debentures the Company. However, it has recently come to
the Companys attention that the amount of the discount assigned to the BCF
should have been limited to the amount of the proceeds allocated to the
convertible instrument. As a result, the Company is restating the discount
associated with the convertible debentures as of June 30, 2003
to reduce it by $5.3 million,
which is an offset to the recorded amount of the convertible debentures. There
is also a corresponding decrease in Additional Paid in Capital of $5.6
million, a decrease in Accumulated Deficit of $0.3 million and an increase
in Total Stockholders Deficit of $5.3 million.
Further, this restatement resulted in a change to the Companys interest expense and net
loss for the three- and six-month period ended June 30, 2003 to reduce the
amounts previously reported by $0.3 million.

Three months and Six months ended June 30, 2003 and 2002

General and administrative expenses for the three months ended June 30, 2003
were $698,507 compared to $564,495 for the three months ended June 30, 2002, an
increase of 24%. General and administrative expenses for the six months ended
June 30, 2003 were $1,278,969 compared to $953,927 for the six months ended
June 30, 2002, an increase of 34%. The increase for both periods was primarily
due to increased fund raising activities.

Research and development expenses for the three months ended June 30, 2003 were
$6,652,299 compared to $9,311,658 for the three months ended June 30, 2002, a
decrease of 29%. Research and development expenses for the six months ended
June 30, 2003 were $11,004,533 compared to $19,001,905 for the six months ended
June 30, 2002, a decrease of 42%. This decrease for both periods is primarily
due to the completion of recruitment and final stages of our clinical trials.
We do not accumulate cost information by major development product. Many costs
are applicable to more than one product. We estimate that 95% of our research
and development costs are spent on gastrointestinal and reproductive system
cancers. There are no payment or penalty milestones associated with any of the
projects, all of which are in Phase II or III clinical trials. We do not
speculate on the timing of approvals by regulatory authorities.

Net loss for the three months ended June 30, 2003 was $7,818,140 compared to
$9,834,698 for the three months ended June 30, 2002, a decrease of 21%. Net
loss for the six months ended June 30, 2003 was $12,741,087 compared to
$19,921,734 for the six months ended June 30, 2002, a decrease of 36%. The
decrease in net loss is primarily a result of our lower research and
development expenses, which was slightly offset by an increase in our amortized
discount and interest expense which was $520,000 for the three and six months
ended June 30, 2003 as compared to none for the three and six months ended June
30, 2002. The amortized discount and interest expense was incurred in
connection with the $20,000,000 senior convertible notes the Company issued
this year. During this period we had no revenues.

Liquidity and Capital Resources

We finance our operations through the sale of our equity securities,
convertible debentures and licensing fees. These funds provide us with the
resources to operate our business, attract and retain key personnel and
scientific staff, fund our research and development program, preclinical
testing and clinical trials, obtain the necessary regulatory approvals and
develop our technology and products.

As of June 30, 2003 we had outstanding $23.0 million in
face value of convertible debentures, up from $3.0 million as of December 31, 2002. There was an initial
discount calculated against the value of the notes of $12.9 million, comprised
of the beneficial conversion feature of $8.3 million and other discounts of
$4.6 million on the notes. The unamortized discount as of June 30, 2003 of
$12.7 million is offset against the $23.0
million and is shown as $10.3 million of convertible debentures in the
accompanying financial statements. Of this amount, $3.0 million is our Series
A Convertible Debenture. Our Series A Convertible Debenture is a convertible,
redeemable, five-year note that matures on December 19, 2007. The Series A
Convertible Debenture bears interest at a rate of 11.0% per annum, payable
annually. The debenture is convertible at the holders option at a conversion
price equal to the average closing price of our common stock, as defined in the
debenture, at the time of conversion. The Series A Convertible Debenture
contains provisions that place a cap on the number of shares of our common
stock issuable upon its conversion, such that the holder thereof shall not have
the right to convert any portion of the Series A Convertible Debenture to the
extent

9



---



##### Table of Contents



that after giving effect to such conversion the holder would
beneficially own more than 19.99% of the number of shares of our common stock
outstanding immediately prior to such conversion.

The remaining $20.0 million in convertible notes were issued in two tranches to
accredited investors during the six months ended June 30, 2003. On April 4,
2003, we issued $15.0 million of convertible, redeemable, 5-year,
interest-bearing senior convertible notes (which we refer to as our 2003 senior
convertible notes) and 5-year warrants to purchase an aggregate total of
1,080,000 shares of our common stock to various accredited investors. On June
12, 2003 we issued an additional $5 million of our 2003 senior convertible
notes and a 5-year warrant to purchase an aggregate total of 360,000 shares of
our common stock to an accredited investor. The senior convertible notes
mature on March 31, 2008. The senior convertible notes bear interest at a rate
of 6.0% per annum, payable quarterly in cash or shares of our common stock, at
our option.

The senior convertible notes are convertible at a fixed price of $2.50 per
share, unless otherwise adjusted prior to conversion pursuant to the price
adjustment provisions set forth therein. The conversion price of the senior
convertible notes will be lowered in the event of a sale by us of our common
stock or securities convertible into our common stock at a per share offering
price less than the conversion price of the senior convertible notes in effect
immediately prior to such sale. The warrants are exercisable into shares of
our common stock at $2.70 per share, unless otherwise adjusted prior to
exercise pursuant to the price adjustment provisions that are substantially
similar to those set forth in the senior convertible notes. The senior
convertible notes and the warrants contain provisions that place a cap on the
numbers of shares of our common stock issuable upon their conversion or
exercise, such that the holders thereof shall not have the right to convert any
portion of the notes to the extent that after giving effect to such conversion
the holders would beneficially own more than 19.99% or 4.99%, as the case may
be for the respective holder, of the number of shares of our common stock
outstanding immediately prior to such conversion or exercise.

On February 24, 2003, we issued 500,000 shares of our common stock at $2.96 per
share and 150,000 warrants at $0.125 per warrant for gross proceeds of
approximately $1.5 million. Each warrant entitles the holder thereof to
purchase a share of our common stock at a price of $2.96 per share within the
next five years.

Cash flow used in operating activities decreased to $18.8 million for the six
months ended June 30, 2003 from $21.2 million for the six months ended June 30,
2002, primarily due to the decrease in our net loss for the period. Cash flow
from investing activities decreased to $0 for the six months ended June 30,
2003 from $1.0 million for the six months ended June 30, 2002. Cash flow from
financing activities decreased to $21.0 million for the six months ended June
30, 2003 compared to $27.7 million for the six months ended June 30, 2002.
During the six months ended June 30, 2003, we received gross proceeds of
approximately $20 million from the sale of the senior convertible notes,
discussed above.

We believe that our existing capital resources, which consist primarily of cash
and short-term cash investments, including the proceeds from the financing
activities described in the preceding paragraphs, will enable us to maintain a
range of operations and satisfy our periodic interest obligations into the
first quarter of 2004.

Inflation

Inflation and changing prices have not had a significant effect on continuing
operations and are not expected to have any material effect in the foreseeable
future. Interest and other income were primarily derived from money-market
accounts.

10



---



##### Table of Contents



Effect Of Recently Issued Accounting Pronouncements

In May 2003, the FASB issued SFAS 150, Accounting for Certain Financial
Instruments with Characteristics of both Liabilities and Equity, effective for
financial instruments entered into or modified after May 31, 2003, and
otherwise is effective at the beginning of the first interim period beginning
after June 15, 2003. This statement establishes standards for how an issuer
classifies and measures certain financial instruments with characteristics of
both liabilities and equity. It requires that an issuer classify a freestanding
financial instrument that is within its scope as a liability (or an asset in
some circumstances). The adoption of SFAS 150 is not expected to have an impact
on the Companys financial position, results of operations or cash flows.

On January 1, 2003, the Financial Accounting Standards Board issued Financial
Accounting Standards Board Interpretation No. 46, Consolidation of Variable
Interest Entities (FIN 46). FIN 46 addresses consolidation of business
enterprises of variable interest entities. FIN 46 is effective immediately for
all variable interest entities created after January 31, 2003 and for the first
fiscal year or interim period beginning after June 15, 2003 for variable
interest entities in which an enterprise holds a variable interest that it
acquired before February 1, 2003. The Company has not acquired any variable
interest entities subsequent to January 31, 2003 and will therefore adopt FIN
46 for its quarterly report for the period
ending September 30, 2003. The Company is currently performing a comprehensive
analysis of the impact of FIN 46, if any, on the Companys financial position,
results of operations or cash flows.

In December 2002, the FASB issued SFAS No. 148, Accounting for Stock-Based
CompensationTransition and Disclosure, an amendment of FASB Statement No.
123. SFAS No. 148 amends SFAS No. 123, Accounting for Stock-Based
Compensation, to provide alternative methods of transition for a voluntary
change to the fair value based method of accounting for stock-based employee
compensation. In addition, SFAS No. 148 amends the disclosure requirements of
SFAS No. 123 to require prominent disclosures in both annual and interim
financial statements about the method of accounting for stock-based employee
compensation and the effect of the method used on reported results. SFAS No.
148 is effective for fiscal years and interim periods ending after December 15,
2002. SFAS No. 148 does not amend SFAS 123 to require companies to account for
employee stock options using the fair value method. We adopted the disclosure
provisions required under SFAS No. 148 effective December 31, 2002.

Critical Accounting Policies

Our significant accounting policies are described in Note 2 to the financial
statements included in our Annual Report on Form 10-K for the year ended
December 31, 2002, filed with the SEC on March 31, 2003. We believe that our
most critical accounting policies include the use of estimates. The impact of
these estimates on results of operations in 2003 and 2002 are not significant.
Our management periodically reviews these policies and estimates, the effect of
which is reflected as a component of net loss in the period in which the change
is known. Such changes to these estimates have not been material to our
results of operations during the three and six months ended June 30, 2003.

Forward-Looking Statements

This quarterly report contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Discussions containing
forward-looking statements may be found in the material set forth in the
section entitled, Managements Discussion and Analysis  as well as in the
quarterly report generally.

These statements concern expectations, beliefs, projections, future plans and
strategies, anticipated events or trends and similar expressions concerning
matters that are not historical facts. Specifically, this quarterly report
contains forward-looking statements regarding:



| |  |  | our expectations as to the adequacy of existing capital resources to
maintain a range of operations and satisfy our periodic interest
obligations through the first quarter of 2004;
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

11



---



##### Table of Contents





| |  |  | our intention to expand our current strategic partnership alliances with
respect to G17DT to treat human cancers in markets worldwide outside of North
America and Europe, monoclonal antibody products to target gastrointestinal
system cancers, worldwide and G17DT for non-cancer therapy, to treat
gastroesophageal reflux disease (GERD) worldwide;
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our beliefs regarding our transition to a company with approved commercial
products and the expectation that this will lead to higher values for our
stockholders; and
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our beliefs regarding the financial impact of certain accounting
pronouncements.
| | - |  | --------------------------------------------------------------------------------

These forward-looking statements reflect our current views about future events
and are subject to risks, uncertainties and assumptions. We caution readers
that certain important factors may have affected and could in the future affect
our actual results and could cause actual results to differ significantly from
those expressed in any forward-looking statement. The most important factors
that could prevent us from achieving our goals, and cause the assumptions
underlying forward-looking statements and the actual results to differ
materially from those expressed in or implied by those forward-looking
statements include, but are not limited to, the following:



| |  |  | our ability to obtain additional financing or reduce our costs and expenses;
| | - |  | ----------------------------------------------------------------------------



| |  |  | our ability to develop, obtain regulatory approval for produce in commercial quantities and gain commercial acceptance for
our products;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to maintain our arrangements and collaborations with third parties for the supply of key materials and
assistance in the manufacture, market, sale and distribution of any product we develop;
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | our ability to enforce our patents and proprietary rights;
| | - |  | ----------------------------------------------------------



| |  |  | our level of debt obligations and the impact of restrictions imposed on us by
the terms of this debt;
| | - |  | -----------------------------------------------------------------------------------------------------



| |  |  | our ability to attract and retain highly qualified scientists and other technical personnel; and
| | - |  | ------------------------------------------------------------------------------------------------



| |  |  | changes in healthcare reform.
| | - |  | -----------------------------

12



---



##### Table of Contents






Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed by the undersigned
thereunto duly authorized.

APHTON CORPORATIONDate: February 25, 2004
    
    By:
    
    /s/ Patrick T. Mooney, M.D.Patrick T. Mooney, M.D.
Chief Executive Officer and President
(Principal Executive Officer)By:
    
    /s/ Frederick W. JacobsFrederick W. Jacobs
Vice President, Chief Financial
Officer, Treasurer and Chief Accounting Officer
(Principal Financial Officer)


13



---



##### Table of Contents



EXHIBIT INDEX

Exhibit Number
    
    Description31.1
    
    Certification by Patrick T. Mooney, M.D., Chief Executive Officer,
pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2
    
    Certification by Frederick W. Jacobs, Chief Financial Officer, pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002.32.1
    
    Certification by Patrick T. Mooney, M.D., Chief Executive Officer,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2
    
    Certification by Frederick W. Jacobs, Chief Financial Officer, pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.


14